No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Emerging Terbinafine Resistant Trichophyton Dermatophytosis, Testing Options and Alternative Treatments: A Systematic Review.

Jegathees Thuvarahan, Holmes Zachary P, Martin Catherine et al. · Australas J Dermatol · 2025

PMID: 40704771Meta-AnalysisFull text (PMC)

A systematic review on the emergence of terbinafine-resistant Trichophyton indotineae in Europe: Time to act?

Ferreira Carolina B, Lisboa Carmen · J Eur Acad Dermatol Venereol · 2025

PMID: 39082800Meta-Analysis

Risk of fetal malformation, spontaneous abortion, and adverse pregnancy outcomes after gestational terbinafine exposure: a systematic review.

Foessleitner Philipp, Farr Alex, Deinsberger Julia · J Dermatolog Treat · 2022

PMID: 35930463Meta-Analysis

Systematic review of severe acute liver injury caused by terbinafine.

Yan Jun, Wang Xiaolin, Chen Shengli · Int J Clin Pharm · 2014

PMID: 24986266Meta-Analysis

Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens.

Gupta A K, Paquet M, Simpson F et al. · J Eur Acad Dermatol Venereol · 2013

PMID: 22632057Meta-Analysis

A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole.

Yin Zhiqiang, Xu Jiali, Luo Dan · J Dermatolog Treat · 2012

PMID: 21801094Meta-Analysis

Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis.

Tey Hong Liang, Tan Andy Soon Leong, Chan Yuin Chew · J Am Acad Dermatol · 2011

PMID: 21334096Meta-Analysis

Use of terbinafine in rare and refractory mycoses.

Revankar Sanjay G, Nailor Michael D, Sobel Jack D · Future Microbiol · 2008

PMID: 18230029Meta-Analysis

Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses.

Kienzler J-L, Queille-Roussel C, Mugglestone C et al. · Curr Med Res Opin · 2007

PMID: 17559730Meta-Analysis

Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen: results of a meta-analysis.

Korting Hans Christian, Kiencke Peter, Nelles Sandra et al. · Am J Clin Dermatol · 2007

PMID: 18039018Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Terbinafine (substance)
SNOMED CT: 373450007
UMLS CUI: C0076110
RxNorm CUI: 37801
Labeler: Sincerus Florida, LLC

Clinical Data

This intervention maps to 6 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.